Novartis AG (NVSEF)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 0.00 |
| Open | 106.21 |
| Bid | 105.03 x 47300 |
| Ask | 115.30 x 40000 |
| Day's range | 105.15 - 106.21 |
| 52-week range | 90.24 - 110.00 |
| Volume | |
| Avg. volume | 21,322 |
| Market cap | 216.569B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 21.88 |
| EPS (TTM) | 4.89 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.76 (3.42%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
ZacksIs a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
ZacksThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
ZacksIonis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
© 2024 Yahoo. All rights reserved.